Treatabolome for finely targeting muscle pathology in LGMD

LGMD's current progress and classification.
In 2025, the large majority of Limb Girdle Muscular Dystrophy(LGMD) patients achieve a genetic diagnosis, due to the recent development of advanced genome sequencing techniques, and the research is open to the future development of specific therapies. Patients' management is so far limited to physical rehabilitation and clinical follow-up of cardiologic and respiratory complications, but several therapies have been tested (including corticosteroids 1 and myostatin inhibitors) in trials with variable success. In this letter, a survey of treatable progress and hurdles occurring in different types of LGMD are covered.